Promethera Biosciences SA NV is a clinical stage pharmaceutical company developing innovative therapies for the treatment of liver diseases – its lead compound HepaStem is currently in Phase IIb for urea cycle disorders. The company also has a HepaStem/H2Stem preclinical program targeting fibrosis and NASH (non-alcoholic steatohepatitis).
Promethera Extends Series C On Interest From Asian Investors
Listen to this article
Dr. John Tchelingerian, CEO of Promethera Biosciences, talks to Scrip senior writer Lucie Ellis on the sidelines of the 2016 BIO-Europe partnering meeting about the company’s liver disease pipeline and series C financing.
Keep up with the top pharma business news of the week. On the go.
More from Start-Ups & SMEs
• By
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
• By
The German group is spinning off from Eckert & Ziegler and listing in Frankfurt, though a leap to the NASDAQ will likely follow once it has more data on a lymphoma theranostic.
• By
BridgeBio spun out oncology assets in May to focus on rare diseases and now it has sliced off a few rare disease candidates for GondolaBio. Also, Avidity and Kymera closed follow-on offerings that grossed $345.1m and $225m, respectively, and Vandria extended its series A round to $30.7m.
• By
With $150m in series A funding, the Versant- and Novartis-backed start-up is betting it can overcome the challenges to getting RNA medicines into the kidney.
More from Business
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.